Habib Fakhrai

This inventor holds 7 USPTO granted patents and 8 published patent applications and 3 EPO patents. Top assignees: Sidney Kimmel Cancer Center, Novarx Corporation. Active years: 1997-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Habib Fakhrai. Retrieved from https://idiyas.com/inventor/habib-fakhrai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 8)

% Patents Active = 71.4

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 1.9

ph-index = 5

Forward Citations = 61(Granted Patents)

Location History:

Oceanside, CA (US) (1997)
La Jolla, CA (US) (1998 - 2012)

Company Filing History:

4 out of 10

Sidney Kimmel Cancer Center

Years Active: 1997-2012

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8293252 - Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization (2012-10-23),

2. 7740837 - Genetically modified cells expressing a TGF beta inhibitor, the cells being lung cancer cells (2010-06-22),

3. 7101543 - Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells (2006-09-05),

4. 6447769 - Compositions and methods for enhanced tumor cell immunity in vivo (2002-09-10),

5. 6120763 - Compositions and methods for enhanced tumor cell immunity in vivo (2000-09-19),

6. 5772995 - Compositions and methods for enhanced tumor cell immunity in vivo (1998-06-30),

7. 5681562 - Lymphokine gene therapy of cancer (1997-10-28),

Title: The Innovative Contributions of Habib Fakhrai

Introduction

Habib Fakhrai is a prominent inventor based in La Jolla, California, known for his significant contributions to cancer therapeutics. With a total of seven patents to his name, Fakhrai has focused on developing innovative solutions to combat various forms of cancer. His work is characterized by a commitment to improving patient outcomes through advanced medical technologies.

Latest Patents

Fakhrai's latest patents include a universal tumor cell vaccine designed for both therapeutic and prophylactic utilization. This universal tumor vaccine incorporates antigens that are characteristic of a wide variety of tumors, allowing for a more comprehensive treatment approach. Additionally, he has developed genetically modified cells that express a TGF beta inhibitor, aimed at reducing the expression of this immunosuppressive agent in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells. These innovations represent a significant advancement in the field of oncology.

Career Highlights

Throughout his career, Fakhrai has worked with notable organizations such as the Sidney Kimmel Cancer Center and Novarx Corporation. His experience in these institutions has allowed him to collaborate with leading experts in cancer research and treatment, further enhancing his contributions to the field.

Collaborations

Fakhrai has collaborated with esteemed colleagues, including Robert E. Sobol and Oliver Dorigo. These partnerships have facilitated the exchange of ideas and expertise, leading to groundbreaking advancements in cancer therapies.

Conclusion

Habib Fakhrai's innovative work in cancer therapeutics has the potential to transform treatment options for patients. His dedication to developing effective solutions underscores the importance of continued research and innovation in the fight against cancer.

Profile summary based on public USPTO records.